{"schema_version":"secwatch.filing_event.v1","accession":"0001804591-24-000045","form_type":"8-K","ticker":null,"cik":"0001804591","company_name":"Chrome Holding Co.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.580177+00:00","generated_at":"2026-05-31T11:08:45.899865+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"23andMe Q1 FY25 revenue down 34% to $40M; net loss improves to $69M; ends Therapeutics Discovery","bullets":["Revenue $40M, down 34% YoY due to lower research revenue after GSK exclusivity end and lower PGS kits/telehealth.","Net loss $69M vs $105M; adjusted EBITDA loss $35M vs $50M.","Cash $170M, down from $216M in prior quarter.","Ceasing Therapeutics Discovery operations effective Aug 9; terminating 30 employees.","Officer Bill Richards resigns effective Aug 23; severance includes $253.5K lump sum, COBRA, RSU acceleration of 90,265 RSUs."],"urls":{"canonical":"https://secwatch.observer/filing/0001804591-24-000045","json":"https://secwatch.observer/filing/0001804591-24-000045.json","markdown":"https://secwatch.observer/filing/0001804591-24-000045.md","text":"https://secwatch.observer/filing/0001804591-24-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1804591/000180459124000045/0001804591-24-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1804591/000180459124000045/me-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:08:45.899865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5fb25127e5","claim":"Bill Richards resigned as Head of Therapeutics Discovery at Chrome Holding Co..","evidence_excerpt":"On August 5, 2024, Bill Richards, the Head of Therapeutics Discovery, and a named executive officer of the Company, tendered his resignation to the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1804591/000180459124000045/0001804591-24-000045-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Head of Therapeutics Discovery"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}